CHC is currently treated with a combination therapy consisting of a weekly injection of pegylated-interferon-α- (Peg-IFN-α-) 2a or 2b plus a daily weight-based dose of ribavirin (RBV) [6, 7]. Here, IFNA17 is linked to cryohydrocytosis.